Recruiting
Breast cancer+1
RecruitingStudy of inavolisib, letrozole and ribociclib in untreated early-stage breast cancer patients with PIK3CA mutation
Registered drugNo placebo
Study of inavolisib, letrozole and ribociclib in untreated early-stage breast cancer patients with PIK3CA mutation
Registered drugNo placebo
- Disease:Breast cancerNeoadjuvant therapy
- Substances:InavolisibLetrozole+1
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Inavolisib
- Sponsor:F. Hoffmann-La Roche AG


